Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DR07FQ
|
|||
| Drug Name |
ION532
|
|||
| Synonyms |
AZD2373
Click to Show/Hide
|
|||
| Drug Type |
Antisense oligonucleotide
|
|||
| Indication | Chronic kidney disease [ICD-11: GB61; ICD-10: N18, N18.9] | Phase 1 | [1] | |
| Nephropathy [ICD-11: GC2Z; ICD-9: 581.3] | Phase 1 | [2] | ||
| Company |
Ionis; AstraZeneca
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Apolipoprotein L1 messenger RNA (APOL1 mRNA) | Target Info | . | [3] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT05351047) A Phase I, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Multiple Ascending Dose Administration to Healthy Male Participants of Sub-Saharan West African Ancestry. U.S.National Institutes of Health. | |||
| REF 2 | ClinicalTrials.gov (NCT04269031) A Phase I, First-in-Human, Randomized, Single-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD2373 Following Single Ascending Dose Administrations to Healthy Male Subjects of African Ancestry. U.S.National Institutes of Health. | |||
| REF 3 | Clinical pipeline report, company report or official report of Ionis | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.